Literature DB >> 28895583

Psychosocial Distress and Quality of Life Impairment Are Associated With Symptom Severity in PPI Non-Responders With Normal Impedance-pH Profiles.

Rena Yadlapati1, Michael Tye2, Laurie Keefer3, Peter J Kahrilas2, John E Pandolfino2.   

Abstract

OBJECTIVES: Up to 50% of patients with reflux symptoms do not manifest a satisfactory symptom response to proton pump inhibitor (PPI) therapy. Our primary aim in this study was to identify factors associated with symptom perception among PPI non-responder phenotypes.
METHODS: This prospective observational cohort study was performed from September 2014 to January 2017 at a single academic medical center and included PPI non-responders who underwent 24-h impedance-pH monitoring and completed a questionnaire set measuring patient-reported symptom severity, quality of life (QOL), and psychosocial distress. Participants were separated into cohorts based on impedance-pH results: on PPI: -acid exposure time (AET)/-symptom-reflux association (SRA), +AET, and -AET/+SRA; off PPI: functional (-AET/-SRA), gastroesophageal reflux disease (GERD) (+AET), and reflux hypersensitivity (RHS) (-AET/+SRA). The primary outcome was abnormal GERD symptom severity defined by GerdQ≥8.
RESULTS: One hundred and ninety-two participants were included. Impedance-pH on PPI was performed on 125: 72 (58%) -AET/-SRA, 42 (34%) +AET, and 11 (9%) -AET/+SRA. Among the -AET/-SRA group, younger age, higher dysphagia scores, QOL impairment, and higher brief symptom index were associated with GerdQ≥8. Among the +AET group, higher number of reflux-associated symptoms and lower distal contractile integral was associated with GerdQ≥8. Impedance-pH off PPI was performed on 67 participants: 39 (58%) functional, 16 (24%) GERD, and 12 (18%) RHS. Among the functional group, higher QOL impairment and dysphagia scores were seen with GerdQ≥8.
CONCLUSIONS: Perceptions of reflux symptoms are associated with psychosocial distress, reduced QOL, and sensation of dysphagia among PPI non-responders with normal impedance-pH. Among PPI refractory GERD patients, patient-reported symptom severity is associated with physiological differences, as opposed to psychosocial factors.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28895583      PMCID: PMC5772841          DOI: 10.1038/ajg.2017.263

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  19 in total

1.  Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?

Authors:  N de Bortoli; I Martinucci; E Savarino; M Bellini; A J Bredenoord; R Franchi; L Bertani; M Furnari; V Savarino; C Blandizzi; S Marchi
Journal:  Neurogastroenterol Motil       Date:  2013-08-29       Impact factor: 3.598

2.  Discomfort intolerance: Development of a construct and measure relevant to panic disorder.

Authors:  Norman B Schmidt; J Anthony Richey; Kathleen Kara Fitzpatrick
Journal:  J Anxiety Disord       Date:  2006

3.  The effect of a sitting vs supine posture on normative esophageal pressure topography metrics and Chicago Classification diagnosis of esophageal motility disorders.

Authors:  Y Xiao; A Read; F Nicodème; S Roman; P J Kahrilas; J E Pandolfino
Journal:  Neurogastroenterol Motil       Date:  2012-08-16       Impact factor: 3.598

4.  The validity and reliability of the reflux finding score (RFS).

Authors:  P C Belafsky; G N Postma; J A Koufman
Journal:  Laryngoscope       Date:  2001-08       Impact factor: 3.325

Review 5.  Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review.

Authors:  Hashem B El-Serag; Stephen Sweet; Christopher C Winchester; John Dent
Journal:  Gut       Date:  2013-07-13       Impact factor: 23.059

6.  The Pain Catastrophizing Scale: further psychometric evaluation with adult samples.

Authors:  A Osman; F X Barrios; P M Gutierrez; B A Kopper; T Merrifield; L Grittmann
Journal:  J Behav Med       Date:  2000-08

7.  Development and validation of the brief esophageal dysphagia questionnaire.

Authors:  T H Taft; M Riehl; J B Sodikoff; P J Kahrilas; L Keefer; B Doerfler; J E Pandolfino
Journal:  Neurogastroenterol Motil       Date:  2016-07-05       Impact factor: 3.598

Review 8.  The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury.

Authors:  J A Koufman
Journal:  Laryngoscope       Date:  1991-04       Impact factor: 3.325

9.  Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care.

Authors:  R Jones; O Junghard; J Dent; N Vakil; K Halling; B Wernersson; T Lind
Journal:  Aliment Pharmacol Ther       Date:  2009-09-08       Impact factor: 8.171

10.  Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome.

Authors:  J H Rubenstein; B Nojkov; S Korsnes; S A Adlis; M J Shaw; B Weinman; J M Inadomi; R Saad; W D Chey
Journal:  Aliment Pharmacol Ther       Date:  2007-08-01       Impact factor: 8.171

View more
  11 in total

Review 1.  The Proton Pump Inhibitor Nonresponder: a Behavioral Approach to Improvement and Wellness.

Authors:  Megan E Riehl; Joan W Chen
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

Review 2.  Medical Therapy of Gastroesophageal Reflux Disease Beyond Proton Pump Inhibitors: Where Are We Heading?

Authors:  Herbert Koop
Journal:  Visc Med       Date:  2018-03-29

3.  Management options for patients with GERD and persistent symptoms on proton pump inhibitors: recommendations from an expert panel.

Authors:  Rena Yadlapati; Michael F Vaezi; Marcelo F Vela; Stuart J Spechler; Nicholas J Shaheen; Joel Richter; Brian E Lacy; David Katzka; Philip O Katz; Peter J Kahrilas; Prakash C Gyawali; Lauren Gerson; Ronnie Fass; Donald O Castell; Jenna Craft; Luke Hillman; John E Pandolfino
Journal:  Am J Gastroenterol       Date:  2018-04-24       Impact factor: 10.864

Review 4.  Comparative Efficacy of Antidepressants for Symptoms Remission of Gastroesophageal Reflux: A Bayesian Network Meta-analysis of Randomized Controlled Trials.

Authors:  Xiao-Bei Si; Lin-Yu Huo; De-Ying Bi; Yu Lan; Shuo Zhang
Journal:  Turk J Gastroenterol       Date:  2021-10       Impact factor: 1.852

5.  ACG Clinical Guidelines: Clinical Use of Esophageal Physiologic Testing.

Authors:  C Prakash Gyawali; Dustin A Carlson; Joan W Chen; Amit Patel; Robert J Wong; Rena H Yadlapati
Journal:  Am J Gastroenterol       Date:  2020-09       Impact factor: 12.045

6.  The Spectrum of Reflux Phenotypes.

Authors:  Lisa B Mahoney; Rachel Rosen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-12

7.  Ambulatory Reflux Monitoring Guides Proton Pump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: A Clinical Trial.

Authors:  Rena Yadlapati; Melina Masihi; C Prakash Gyawali; Dustin A Carlson; Peter J Kahrilas; Billy Darren Nix; Anand Jain; Joseph R Triggs; Michael F Vaezi; Leila Kia; Alexander Kaizer; John E Pandolfino
Journal:  Gastroenterology       Date:  2020-09-16       Impact factor: 22.682

8.  Esophageal Hypervigilance and Visceral Anxiety Are Contributors to Symptom Severity Among Patients Evaluated With High-Resolution Esophageal Manometry.

Authors:  Dustin A Carlson; C Prakash Gyawali; Sabine Roman; Marcelo Vela; Tiffany H Taft; Michael D Crowell; Karthik Ravi; Joseph R Triggs; Farhan Quader; Jacqueline Prescott; Frederick T J Lin; Francois Mion; Dario Biasutto; Laurie Keefer; Peter J Kahrilas; John E Pandolfino
Journal:  Am J Gastroenterol       Date:  2020-03       Impact factor: 12.045

9.  Esophageal hypervigilance is prevalent across gastroesophageal reflux disease presentations.

Authors:  Livia Guadagnoli; Rena Yadlapati; Tiffany Taft; John E Pandolfino; Michael Tye; Laurie Keefer
Journal:  Neurogastroenterol Motil       Date:  2021-01-11       Impact factor: 3.960

Review 10.  Gut-focused hypnotherapy for Functional Gastrointestinal Disorders: Evidence-base, practical aspects, and the Manchester Protocol.

Authors:  Dipesh H Vasant; Peter J Whorwell
Journal:  Neurogastroenterol Motil       Date:  2019-02-27       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.